NRx Pharmaceuticals, Inc. Q3 2026 Earnings Recap
NRx shares surged 30.2% after earnings, as investors responded to its first FDA drug approval, first commercial order, and roughly $20 million in quarter-end cash. The transcript also points to an early commercial buildout, though management’s profitability ambitions remain forward-looking.
The numbers
Reported results against what analysts expected.
Key takeaways
From the Q3 2026 earnings call.
- NRx ended the third quarter with about $20 million in cash and cash equivalents and said it had eliminated all convertible debt.
- The company has a 17-person sales force; management said its first customer order was received the day before the call.
- NRx said its sterile injectable initiative received its first drug approval and cited an estimated $400 million U.S. market for sterile injectable ketamine, growing more than 17% annually.
- Management described four divisions—pharmaceuticals, HOPE Therapeutics, NRx Defense Systems, and GeNeuro—and said each has potential near-term profitability; these are targets, not reported outcomes.
- The CEO said the company aims to demonstrate a path to profitability in 2027; the call provided no specific profitability forecast or detailed quarterly financial results in the supplied excerpt.
Track earnings for the stocks you own
Add your portfolio once, by connecting your broker or importing your history. When a company you hold reports, you get a recap like this one by email, with how the stock moved.
Also published on November 19, 2026
This summary was written by AI from the official earnings call transcript. It is for information only and is not financial advice. For NRXP's price history and fundamentals, see the NRXP stock page.